Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19617362 | 0.85 | KMT2A (0.34) | KMT2ACYP2C19CYP1A2GAATRPV1 | |
| SCHEMBL28503146 | 0.83 | KMT2A (0.31) | KMT2ACYP2C19CYP1A2GAATRPV1 | |
| SCHEMBL26010294 | 0.82 | CYP1A2 (0.34) | KMT2ACYP2C19CYP1A2GAA | |
| SCHEMBL21777116 | 0.81 | KMT2A (0.38) | KMT2ACYP2C19CYP1A2GAA | |
| SCHEMBL19617493 | 0.81 | PARP1 (0.40) | KMT2AKDM4EMAPT | |
| SCHEMBL24780348 | 0.78 | CYP1A2 (0.37) | KMT2ACYP2C19CYP1A2GAA | |
| SCHEMBL29903126 | 0.78 | CYP1A2 (0.37) | KMT2ACYP2C19CYP1A2GAA | |
| SCHEMBL4192572 | 0.78 | CCNA2 (0.39) | KMT2ACYP2C19CYP1A2MAPTTRPV1 | |
| SCHEMBL28499362 | 0.77 | CYP1A2 (0.34) | KMT2ACYP2C19CYP1A2GAA | |
| SCHEMBL31661054 | 0.77 | PARP1 (0.35) | KMT2ACYP2C19CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739102-B2 | Fused pyrimidine compounds as KRAS inhibitors | INCYTE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739102-B2 | Fused pyrimidine compounds as KRAS inhibitors | KRAS, NRAS, HRAS | KMT2A 3342/4885CYP2C19 3567/4885CYP1A2 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.